COMPANY

PanTher Therapeutics

HQ: Austin, TX source · panthertx.com ↗ · Southwest

Our lead clinical-stage program, PTM-101, is being developed for the treatment of pancreatic cancer. From company website Source · Oct 12, 2026

Keywords: cancer Pancreatic Ductal Adenocarcinoma Borderline Resectable Pancreatic Adenocarcinoma Locally Advanced Pancreatic Adenocarcinoma Pancreatic Cancer PTM-101

Location: Austin, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Apr 14, 2025 Trial start Phase 1: PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) · NCT06673017

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06673017	PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1	Recruiting	Apr 14, 2025	2026-12 (estimated)